6 results

Prothena spun out of Irish drugmaker Elan in 2012. Photograph: Istock

Dublin-headquartered drug developer Prothena has agreed to sell its experimental heart therapy PRX004 in a deal worth up to $1.2 billion (€ 1.02 billi(...)

The offering is expected to close on Friday

Shares in Dublin-based, Nasdaq-listed biotech company Prothena jumped by almost 17 per cent on Wednesday after it said it intends to raise $67.8 milli(...)

Immatics Biotechnologies chairman Peter Chambre and Alkermes director Shane Cooke are to join the board of UDG Healthcare as non-executive directors. Photograph: David Sleator

Healthcare services provider UDG Healthcare has appointed two new non-executive directors to its board. Immatics Biotechnologies chairman Peter Chamb(...)

Prothena is now discontinuing development of the antibody-based medicine for the condition.

Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 per cent yesterday after its main drug for treating a rare(...)

US president Donald Trump and US vice president Mike Pence: investors seemed underwhelmed by Trump’s tax cuts. Photograph: Carlos Barria/Reuters

Technology stocks have just suffered another week of underperformance, prompting much chatter as to whether investors are having second thoughts about(...)

Daybreak will act as an outsourced contractor, providing IT systems and backup to Elan and other biotech firmsbinary code

Up to 50 high-end engineering jobs will be created in Dublin through a new biotech systems management company headed up by Irish expats in Silicon Val(...)